Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab

Background: Patients having undergone B-cell-depletion with anti-CD20-antibodies have a higher risk of mortality, delayed viral clearance and prolonged infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report two cases of patients with persistent coronavirus disease 2...

Full description

Bibliographic Details
Main Authors: David Totschnig, Daniel Doberer, Renate Haberl, Christoph Wenisch, Arschang Valipour
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:IDCases
Subjects:
SARS-CoV-2
COVID-19
Monoclonal antibody
Sotrovimab
B-cell depletion
Anti-CD20-antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250922001561

Internet

http://www.sciencedirect.com/science/article/pii/S2214250922001561

Similar Items